| 10th week of 2022 patent applcation highlights part 11 |
| Patent application number | Title | Published |
|---|
| 20220072080 | ALOE EXTRACT AND METHODS FOR PRODUCING THE SAME - Disclosed herein is a method for preparing an | 2022-03-10 |
| 20220072081 | METHODS OF USING IRON-FREE SUPPLEMENTS TO ENHANCE CYTOPROTECTION AGAINST ANEMIA IN HUMANS - A multi-nutrient containing formulation is provided which is encapsulated in phospholipid structures. The multi-nutrient containing formulation may be administered to human subjects to restore hemoglobin in red blood cells (RBCs) and restore white blood cells. The multi-nutrient containing formulation may be administered to human subjects to normalize platelet morphology in anemic subjects. | 2022-03-10 |
| 20220072082 | POLYPEPTIDE, POLYPEPTIDE FRAGMENT, DERIVATIVE THEREOF, AND APPLICATIONS THEREOF - Disclosed in the present invention are a polypeptide fragment, a derivative of the polypeptide fragment, and applications of the derivative of the polypeptide in the preparation of drugs for preventing and treating fibrosis diseases. | 2022-03-10 |
| 20220072083 | COMPOSITION FOR IMPROVING OR PREVENTING NONALCOHOLIC FATTY LIVER - An object of the present invention is to provide a composition for preventing or improving fat deposition on the liver in spite of the alcohol intake history of a level that a liver disease is not caused. The inventors found that glutathione has an effect of preventing or improving fat deposition on the liver, which is not caused by alcohol, and completed the present invention. Among nonalcoholic fat diseases, the present invention is particularly effective in an early stage of the treatment or in a case where treatment for another disease is not performed. | 2022-03-10 |
| 20220072084 | THERAPEUTIC NANOCONJUGATES AND USES THEREOF - The present invention relates to nanostructured conjugates, more specifically to nanostructured fusion proteins suitable for the selective delivery of their conjugated therapeutic agents to specific cell and tissue types. It also relates to nanoparticles comprising such nanostructured proteins and the therapeutic uses thereof. | 2022-03-10 |
| 20220072085 | Ready-To-Use Carfilzomib Compositions - The present invention provides a stable, non-aqueous, ready-to-use parenteral composition comprising: carfilzomib or pharmaceutically acceptable salt thereof, acidifying agent, optionally a surfactant, one or more solvents or co-solvents. | 2022-03-10 |
| 20220072086 | CARBETOCIN DRUG PRODUCT AND PROCESS FOR PREPARING SAME - The present disclosure includes a method of making an improved carbetocin drug product. The disclosed method for making an improved carbetocin drug product comprises agitating a carbetocin preparation containing an aqueous solution of carbetocin and one or more excipients for a period of time to initiate the formation of aggregate-forming solids and filtering off the aggregates that form before further processing the remaining carbetocin into a final drug product. The present disclosure also relates to an improved carbetocin drug product, wherein the drug product is substantially free of aggregate-forming solids. The disclosed carbetocin drug product can be used for the treatment of a neurodevelopmental disorder, such as Präder-Willi syndrome. Additionally, the disclosed carbetocin drug product shows content uniformity of carbetocin over long periods of time before and after one or more freeze/thaw cycles, provides enhanced convenience and patient compliance, and/or are highly concentrated. | 2022-03-10 |
| 20220072087 | SPECIFIC COMBINATION THERAPY FOR TREATMENT OF PANCREATIC CANCER - A method of treating metastatic pancreatic adenocarcinoma in a subject in need thereof is provided. The method comprises administering to the subject a therapeutically effective amount of a peptide set forth in SEQ ID NO: 1 and a chemotherapy comprising irinotecan, fluorouracil (5-FU) and leucovorin (LV), thereby treating the metastatic pancreatic adenocarcinoma, wherein the subject is not subjected to treatment with an anti-PD-1. | 2022-03-10 |
| 20220072088 | REDUCING CLOSTRIDIUM PERFRINGENS VIRULENCE USING INHIBITORS OF AGR-LIKE QUORUM SENSING - This disclosure provides materials and methods for reducing production of virulence factors in | 2022-03-10 |
| 20220072089 | CANCER THERAPEUTIC COMPOSITIONS AND METHODS - The invention relates, in part, to compounds, compositions, and methods comprising Thiostreopton (TS) that are useful to treat cancer in cells and subjects. | 2022-03-10 |
| 20220072090 | NOVEL COMPOSITION - There is provided inter alia an aqueous solution composition of pH in the range 5.0 to 8.0 comprising: —daptomycin or an analogue thereof, or a salt thereof; —a divalent metal cation; and —optionally one or more buffers being substances having at least one ionisable group with a pK | 2022-03-10 |
| 20220072091 | NOVEL COMPOSITION - The invention provides inter alia an aqueous solution composition of pH in the range 6.0 to 8.0 comprising:—daptomycin or an analogue thereof, or a salt thereof;—a divalent metal cation; and—one or more salts which are not divalent metal cation salts or amino acid salts or buffer salts at a total concentration of 300 mM or more. | 2022-03-10 |
| 20220072092 | COMPOSITIONS AND METHODS OF TREATING MELANOMA - The invention provides compositions, kits and methods to treat a hyperproliferative disorder with an agent that increases expression of MCR1 and an MCR1 ligand. The invention also provides a method of treating drug-resistant melanoma, comprising administering an MCR1 ligand to a patient in need thereof. | 2022-03-10 |
| 20220072093 | CYCLOSPORIN ANALOGUES AND USES THEREOF - A compound for use in the treatment or prevention of acute or chronic inflammatory disorders wherein the compound is a compound of Formula 1: | 2022-03-10 |
| 20220072094 | Compositions and Methods for Uncoupling TrkB Receptor from PLC Gamma 1 for the Treatment of Epilepsy and Anxiety-Like Disorder - The invention provides pharmaceutical compositions and methods of use thereof for preventing or ameliorating disorders of the nervous system. More specifically, the invention provides pharmaceutical compositions, including phosphopeptides that when administered disrupt the physical interaction of TrkB with its signaling effector, phospholipase Cγ1 (PLCγ1). The invention further provides method of treatment comprising administering phosphopeptides that uncouple TrkB from PLCγ1 in order to prevent and/or ameliorate nervous system disorders such as epilepsy, anxiety, and seizures. | 2022-03-10 |
| 20220072095 | METHODS AND COMPOSITIONS FOR TREATING SKIN DISEASES - Disclosed are compositions and methods for treating skin diseases mediated by inflammation that is caused by microbial, autoimmune, allergic, metabolic, neoplastic, and physical factors and insults (wounds, burns, UV light and radiation). In one aspect, the compositions and methods disclosed herein can also be used to enhance clearance of microbes from infected skin and subcutaneous tissue, in a subject. Also disclosed herein are compositions and methods for reducing levels of stress-responsive transcription factors and metabolic transcription factors in a cell in a subject with inflammation-mediated skin diseases. | 2022-03-10 |
| 20220072096 | WHEY PROTEIN MICELLES AGAINST MUSCLE ATROPHY AND SARCOPENIA - The present invention relates to whey protein micelles for use in the treatment and/or prevention of a condition linked to a reduced concentration of plasma amino acids in a patient. A further aspect of the invention is a meal replacement comprising whey protein micelles. | 2022-03-10 |
| 20220072097 | PEPTIDES AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS - Disclosed herein are compositions and methods for treating and preventing neurodegenerative diseases, such as Alzheimer's disease. In some embodiments, the composition comprises a peptide that disrupts the binding between PTPσ and APP, preventing β-amyloidogenic processing of APP without affecting other major substrates of β- and γ-secretases. Alternatively, in some embodiments, an antibody or a fragment of an antibody against PTPσ or APP may be used to disrupt the binding between PTPσ and APP. In some embodiments, the composition comprises compounds or enzymes, which restore perineuronal balance of PTPσ ligands CS and HS, thereby preventing abnormally increased β-amyloidogenic processing of APP. Compositions and methods disclosed herein can be used in combination to treat and prevent neurodegenerative diseases. | 2022-03-10 |
| 20220072098 | BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF - Bolaamphiphilic compounds are provided according to formula I: | 2022-03-10 |
| 20220072099 | METHODS FOR TREATMENT OF BILE ACID-RELATED DISORDERS AND PREDICTION OF CLINICAL SENSITIVITY TO TREATMENT OF BILE ACID-RELATED DISORDERS - Provided herein are methods of using 7α-hydroxy-4-cholesten-3-one (C4) in predicting the clinical sensitivity to treatment of bile acid-related and associated disorders with treatment peptides, such as variants of fibroblast growth factor 19 (FGF19) proteins and peptide sequences (and peptidomimetics) and fusions of FGF19 and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), and variants of fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics). | 2022-03-10 |
| 20220072100 | METHODS OF TREATING CANCER, INFECTIOUS DISEASE, AND AUTOIMMUNE DISEASE USING CHEMOKINES - The current invention is related to the prevention and treatment of diseases including cancer, autoimmune disease, and infectious disease using chemokines and the receptors to which they agonize. It has been found that certain chemokines, including CXCL4, CXCL9, CXCL10, and CXCL12 as well as CCL5 have various effects on toll-like receptors in various cell types and these can be utilized for disease treatment and prevention. | 2022-03-10 |
| 20220072101 | HARNESSING INFLAMMATION TO TREAT NEURODEVELOPMENTAL DISORDERS - Described herein are methods and compositions related to a method of treating a neurodevelopmental disorder in a subject in need thereof, the method comprises administering to the subject an agent that increases the level or activity of interleukin-17a (IL-17a) in the brain. The method can further comprise administering an agent that increases the permeability of the blood brain barrier. | 2022-03-10 |
| 20220072102 | TREATMENT OF INFLAMMATORY CONDITIONS BY DELIVERY OF INTERLEUKIN-1 RECEPTOR ANTAGONIST FUSION PROTEIN - The present invention provides, among other things, methods of treating post-cardiac injury syndrome (PCIS) or pericarditis, comprising a step of administering to a subject in need of treatment an interleukin-1 receptor-Fc fusion protein at a therapeutically effective dose and an administration interval for a treatment period sufficient to improve, stabilize or reduce one or more signs and symptoms of pericarditis relative to a control. | 2022-03-10 |
| 20220072103 | Combination therapy of PD-1-targeted IL-2 variant immunocytokines and antibodies against human PD-L1 - The present invention relates to the combination therapy of specific PD-1-targeted IL-2 variant immunocytokines with specific antibodies which bind human PD-L | 2022-03-10 |
| 20220072104 | MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF - Methods and compositions are provided for extending the half-life of a therapeutic agent. A modified therapeutic agent (mTA) comprises a therapeutic agent, a staple, and a half-life extending molecule. The mTAs disclosed herein may be used to treat a disease or a condition in a subject in need thereof. | 2022-03-10 |
| 20220072105 | RAPID-ACTING INSULIN COMPOSITIONS - The invention is a composition of human insulin or insulin analog that includes specific concentrations of citrate, chloride, in some cases including the addition of sodium chloride, zinc and, optionally, magnesium chloride and/or surfactant, and that has faster pharmacokinetic and/or pharmacodynamic action than commercial formulations of existing insulin analog products. | 2022-03-10 |
| 20220072106 | DECORIN FOR ITS USE IN THE TREATMENT OF DIABETES - The disclosure relates to decorin or a composition containing decorin for use in the treatment of type 1 diabetes (particularly in the context of transplanting pancreatic islet cells), type 2 diabetes or gestational diabetes. | 2022-03-10 |
| 20220072107 | NUTRITIONAL COMPOSITION FOR INDUCING A FEELING OF SATIETY, A BETTER SLEEP AND/OR LIMITING NOCTURNAL AWAKING IN INFANTS OR YOUNG CHILDREN - The invention relates to a nutritional composition for infants and young children comprising proteins, carbohydrates and lipids, wherein said proteins comprise ionic complexes of lactoferrin with acid milk proteins, said complexes having a negative charge at the pH of the infant formula. The nutritional composition is used for providing a satiety feeling and/or a better sleep and/or limiting nocturnal awaking in infants or young children. | 2022-03-10 |
| 20220072108 | NEW COMPOSITIONS AND METHODS FOR THE TREATMENT OF ACNE VULGARIS - The present invention relates to the use of a protein, more specifically a | 2022-03-10 |
| 20220072109 | ANTI INFLAMMATORY COMPOSITION - The present invention provides a method for treating or preventing inflammation caused by neutrophils and a pharmaceutical composition for such treatment or prevention. Specifically, provided is a pharmaceutical composition or the like for treating or preventing inflammation caused by neutrophils that contains a complex in which lysozyme and chitosan are bonded. | 2022-03-10 |
| 20220072110 | PLASMINOGEN FOR TREATING AND PREVENTING MICROTHROMBOSIS - The present invention relates to plasminogen for use in a method for preventing or treating a thrombotic event in a patient, wherein the patient is at risk of developing or is suffering from microthrombi. | 2022-03-10 |
| 20220072111 | AGENT FOR USE IN THE CASE OF FRUCTOSE INTOLERANCE - There is provided a method for treating or reducing the effects of fructose intolerance and health problems associated with excessive fructose intake by administration of glucose isomerase. Other embodiments are also disclosed. | 2022-03-10 |
| 20220072112 | PROCESS FOR THE PRODUCTION OF A DNA VACCINE FOR CANCER IMMUNOTHERAPY - The present invention relates to a method for producing a DNA vaccine for cancer immunotherapy comprising at least the steps of (a) transforming an attenuated strain of | 2022-03-10 |
| 20220072113 | ANTIGEN SPECIFIC MULTI EPITOPE VACCINES - The presently described subject matter relates to cancer vaccines composed of the signal peptide domain of tumor associated antigens or proteins. The described peptide vaccines have multiple MHC class I and class II epitopes which are highly abundant in the population. Therefore, these vaccines induce a strong, comprehensive immune response against the target proteins in the majority of the vaccinated population, and thereby induce an immune reaction against tumors expressing such target proteins. Specifically, the presently described subject matter relates to peptide vaccines composed of the signal peptide domain of Mucin (MUC1), BAGE-1 or ARMET, and their use for the treatment of cancers which express Mucin (MUC1), BAGE-1 or ARMET. | 2022-03-10 |
| 20220072114 | POPULATION-BASED IMMUNOGENIC PEPTIDE IDENTIFICATION PLATFORM - The disclosure relates to methods of identifying fragments of a polypeptide that are immunogenic for a specific human subject, methods of preparing pharmaceutical compositions comprising such polypeptide fragments, pharmaceutical compositions comprising such polypeptide fragments, and methods of treatment using such compositions. The methods comprise identifying a fragment of the polypeptide that binds to multiple HLA of individual subjects. | 2022-03-10 |
| 20220072115 | MALARIA ANTIGENS ON THE SURFACE OF ERYTHROCYTES AND MEROZOITES AND PROTECTIVE ANTIBODIES - Provided herein are compositions and methods for treating and preventing malaria. The vaccine of the invention is directed to the protein encoded by the PF3D7_1134300 gene, or fragments of the protein, which are Pf Erythrocyte Membrane and Merozoite Antigenl (PfEMMAI). Exemplary fragments include Fragment 1, Fragment 2, or a C-terminal fragment of PfEMMAI. | 2022-03-10 |
| 20220072116 | BACTERIAL VACCINE - The present document discloses a method for producing a bacterial vaccine composition against bacterial diseases in animals, such as tetrapods or fish, wherein said bacterial vaccine composition comprises inactivated bacteria of the bacterium causing said bacterial diseases. The method involves exposing the bacteria to different growth conditions and then preparing a bacterial vaccine composition where the bacteria are exposed to different growth conditions. With vaccines prepared by the present method, bacterial diseases that previously had not been able to be cured could be treated or the effect of the treatment was more long-lasting. | 2022-03-10 |
| 20220072117 | Dimethyl Fumarate and Vaccination Regimens - Provided herein is a method of treating or preventing a disease or disorder (e.g., MS) in a subject in need thereof, comprising (a) administering to the subject a first dose of a pharmaceutical composition comprising a fumarate agent (e.g., DMF) for a first dosing period; (b) administering a vaccine; and (c) administering to the subject a second dose of the pharmaceutical composition for a second dosing period. | 2022-03-10 |
| 20220072118 | IMMUNOGENIC COMPOSITIONS - Technologies for the prevention and/or treatment of nosocomial infections. | 2022-03-10 |
| 20220072119 | PEPTIDE FRAGMENTS FROM FILOVIRUSES AND THEIR USES - Isolated peptides comprising one or more antigenic sites of filovirus glycoprotein and methods of their use and production are disclosed. Nucleic acid molecules encoding the peptides are also provided. In several embodiments, the peptides can be used to induce an immune response to filovirus glycoprotein, such as Zaire ebolavirus glycoprotein, in a subject, for example, to treat or prevent infection of the subject with the virus. | 2022-03-10 |
| 20220072120 | NANOPARTICLE-BASED INFLUENZA VIRUS VACCINES AND USES THEREOF - Nanoparticles and vaccines containing these nano particles that elicit an immune response against hemagglutinin (HA) proteins from a broad range of influenza viruses are provided. The nanoparticles are made from self-assembling proteins, at least one of which is joined to an immunogenic portion of an influenza HA protein. This immunogenic portion is displayed on the nanoparticle surface, making the nanoparticles useful for vaccinating subjects against influenza virus. | 2022-03-10 |
| 20220072121 | CORONAVIRUS IMMUNOGENIC COMPOSITIONS AND USES THEREOF - CORONAVIRUS IMMUNOGENIC COMPOSITIONS AND USES THEREOF Provided in the present disclosure are immunogenic compounds, pharmaceutical formulations thereof and their use for inducing a protective immune response against 2019 novel coronavirus (SARS-CoV-2) infection and variants in a mammal. | 2022-03-10 |
| 20220072122 | METHOD FOR GENERATING RECOMBINANT POXVIRUSES - Disclosed herein are methods for the rapid generation of recombinant viruses, for example, to enable vaccine development. | 2022-03-10 |
| 20220072123 | METHODS OF INTRODUCING FOOD ALLERGENS - Methods for introducing allergens to a human subject are provided. | 2022-03-10 |
| 20220072124 | COMPLEX FOR ENHANCING IMMUNE RESPONSE - A novel composite, and research on the preparation, application and the like of the composite. The method for preparing the composite comprises: contacting a polyinosinic-polycytidylic acid, at least one cationic stabilizer, and a soluble calcium salt in a liquid reaction system, the cationic stabilizer being a water-soluble non-antibiotic amino compound having a molecular weight of less than or equal to 5 kDa, or a graft copolymer formed by a water-soluble non-antibiotic amino compound and one or more of methoxypolyethylene glycol, polyethylene glycol, polyethylenimine, folic acid, or galactose. The composite has moderate viscosity and molecular weight, is convenient to use in pharmaceutical application, has stable chemical properties, is not easy to be degraded in long-term storage, and is safe to use. The composite, if used alone, can significantly enhance the non-specific immune response of the body and achieve the purpose of preventing and treating diseases, and other drugs, and can achieve better anti-tumor, anti-viral and anti-(super) bacteria efficacy and is easily absorbed by patients, if used in combination with other drugs. | 2022-03-10 |
| 20220072125 | COMPOSITIONS AND METHODS FOR INDUCTION OF TH17 CELLS - Strains of human-derived bacteria have been obtained from complex fecal samples and shown to induce accumulation of Th17 cells in the intestine and promote immune functions. Pharmaceutical compositions containing these bacteria can be used as anti-infectives and as adjuvants in mucosal vaccines. | 2022-03-10 |
| 20220072126 | PREPARATION INCLUDING VACCINE ADJUVANT - Provided is a composition that is useful as a vaccine adjuvant and has excellent storage stability and immunostimulatory activity. Specifically provided is a freeze-dried preparation that has high storage stability, said preparation containing a (4E,8E,12E,16E,20E)-N-{2-[{4-[(2-amino-4-{[(3S)-1-hydroxyhexan-3-yl]amino}-6-methylpyrimidin-5-yl)methyl]benzyl}(methyl)amino]ethyl}-4,8,12,17,21,25-hexamethylhexacosa-4,8,12,16,20,24-hexaenamide, squalane, a hydrophilic surfactant, and an oleophilic surfactant, and being characterized by containing an ascorbic acid-based antioxidant and an excipient. | 2022-03-10 |
| 20220072127 | METHODS FOR TREATING PATIENTS WITH REFRACTORY HYPERCHOLESTEROLEMIA - The present invention provides methods for treating patients suffering from refractory hypercholesterolemia. The methods of the invention provide for lowering at least one lipid parameter in the patient by administering a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to ANGPTL3 in combination with a therapeutically effective amount of a statin, a first lipid lowering agent other than a statin, and a second lipid lowering agent other than a statin. | 2022-03-10 |
| 20220072128 | ULTRASOUND-INDUCED CONVECTION FOR DRUG DELIVERY AND TO DRIVE GLYMPHATIC OR LYMPHATIC FLOWS - The utility of intrathecal delivery is limited by the poor brain and spinal cord parenchymal uptake of intrathecally delivered agents. A simple noninvasive transcranial ultrasound protocol is provided that significantly increases the brain parenchymal uptake of intrathecally administered drugs and antibodies. This protocol of transcranial ultrasound can accelerate glymphatic fluid transport from the cisternal space into the parenchymal compartment. The low intensity and noninvasive approach of ultrasound in this protocol underscores the ready path to clinical translation of this technique. This low-intensity transcranial ultrasound protocol can be used to directly bypass the blood-brain barrier for whole-brain delivery of a variety of agents. Additionally, this protocol is useful as a means to probe the causal role of the glymphatic system in the variety of disease and physiologic processes to which it has been correlated. | 2022-03-10 |
| 20220072129 | NOBLE METAL NANOPARTICLES WITH RADIAL PORES AND METHODS FOR ANTITUMOR TREATMENTS - Nanoparticles having radially-oriented pores are fabricated from a noble metal. The pores have a specific geometrical shape, such as a circle, triangle, hexagon or other polygon. The nanoparticles are administered to a subject to form a nanoparticle-loaded tumor, which is targeted with a radiation beam as part of a radiotherapeutic treatment. The pores redirect photons of the radiation beam to intensify and enhance the dose received by tumor cells, while concomitantly reducing the dose received by surrounding cells and/or tissues. The nanoparticles may be combined with a radiosensitizing drug or agent, administered together or separately, to form a dose-enhancement composition that further intensifies the received dose of radiation at the target. | 2022-03-10 |
| 20220072130 | STABLE MICROSPHERES, METHOD OFF ABRICATION AND USE THEREOF - Stable and durable polymeric microbubbles of a 1-10 μm size range are disclosed. The microbubbles are synthesized from the co-polymer poly lactic-co-glycolic acid (PLGA), which provides a plurality of PLGA microbubbles presenting diverse cavitation activities. The PLGA microbubbles are particularly suitable for cavitation enhancement purposes and are applicable in various clinical procedures such as ablation or enhancement of uptake of chemical or biological therapy in cells and tissue. | 2022-03-10 |
| 20220072131 | Dihydroxyphenyl Neurotransmitter Compounds, Compositions And Methods - The present invention relates to new dihydoxyphenyl modulators of neurotransmitter levels, pharmaceutical compositions thereof, and methods of use thereof. | 2022-03-10 |
| 20220072132 | FULVESTRANT FORMULATIONS - Long term storage stable fulvestrant-containing compositions are disclosed. The compositions can include fulvestrant; a solvent selected from dimethyl sulfoxide (DMSO), glycofurol, N-methyl pyrrolidone, and mixtures thereof; an oil mixture selected from a mixture of caprylic and capric triglycerides, a mixture of caprylic, capric and linoleic triglycerides, a mixture of caprylic, capric and succinic triglycerides, and a mixture of propylene glycol dicaprylate and propylene glycol dicaprate; and a sustained release member selected from benzyl benzoate, dihydrolipoic acid, benzyl alcohol and lipoic acid. The fulvestrant-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 24 months of storage at a temperature of from about 5° C. to about 25° C. | 2022-03-10 |
| 20220072133 | Pharmaceutical Compositions Having Improved Storage Stability - The present invention relates to a pharmaceutical composition that provides long-term stability of a hydrolytically labile antipsychotic agent | 2022-03-10 |
| 20220072134 | TEMPERATURE-RESPONSIVE DEGRADABLE HYDROGELS - A polymer composition can include an aqueous vehicle and a temperature-responsive degradable polymer having a polymer including a LCST-imparting unit and a lactone-bearing unit including a pendent lactone group. The number of LCST-imparting units is greater than the number of lactone-bearing units. The temperature-responsive degradable polymer has an initial lower critical solution temperature (LCST) of 37° C. or below. The polymer composition can have a pH lower than 7. | 2022-03-10 |
| 20220072135 | HYDROPHOBICALLY MODIFIED POLYPEPTOIDS AND USES THEREOF - A variety of hydrophobically modified polypeptoids are provided. The hydrophobically modified polypeptoids can include a polyimide backbone having a random copolymer of two or more different types of repeat units, where one or more of the repeat units have nitrogen atom having a hydrophobic substituent attached thereto. Methods of making the hydrophobically modified polypeptoids are also provided, as well as uses of the hydrophobically modified polypeptoids, for example in liposomal drug delivery. | 2022-03-10 |
| 20220072136 | PROTEIN BASED EXCIPIENT FOR ACTIVE PHARMACEUTICAL INGREDIENTS - Provided herein is a pharmaceutical formulation comprising a protein based excipient in combination with an active pharmaceutical ingredient (API) wherein said formulation is substantially amorphous and form a substantially homogenous mixture; and further a method for producing said pharmaceutical formulation; and said pharmaceutical formulation for use as a medicament. | 2022-03-10 |
| 20220072137 | LINKER FOR ANTIBODY-DRUG CONJUGATES AND ITS USE - The present invention provides a linker for preparing antibody-drug conjugates and antibody-drug conjugates prepared by the linker, as well as use of the antibody-drug conjugates in a medicament for treating tumor. The linker is capable of coupling simultaneously with the thiol group or amino group on the antibody or functional fragment of the antibody, especially it is capable of coupling with 2, 3 or 4 thiol groups on the antibody or functional fragment of the antibody. A coupled product is uniform and structurally stable. | 2022-03-10 |
| 20220072138 | NRTI THERAPIES - Polymer-of-prodrug (POP) materials enable new nucleoside reverse transcriptase inhibitor (NRTI) therapy strategies. The materials are prodrugs of NRTIs in the form of polymers. Suitable materials include products which are polymeric NRTI delivery systems comprising polymeric materials which are capable of degradation after administration to release NRTIs or NRTI prodrugs which themselves are capable of metabolism to the parent NRTIs. The NRTIs may optionally be selected from tenofovir (TFV), emtricitabine (FTC), lamivudine (3TC) and MK-8591 (EFdA). The invention facilitates long-acting (LA) regimens. Constructs of the materials may be in the form of injectable compositions or implants. | 2022-03-10 |
| 20220072139 | STEREOCOMPLEXES FOR THE DELIVERY OF ANTI-CANCER AGENTS - Disclosed herein are stereocomplexes for the delivery of one or more anti-cancer agents. The stereocomplexes exhibit low toxicity and are biodegradable while also providing for controlled release of one or more anti-cancer agents at tumor sites. The stereocomplexes can be designed such that the anti-cancer agents operate synergistically and may optionally include additional targeting groups and functionalities. The stereocomplexes disclosed herein can be combined with pharmaceutically-acceptable carriers and/or excipients to form pharmaceutical compositions. By varying the amount of each anti-cancer agent in the stereocomplex, specific types of tumors and cancer cell lines can be treated. | 2022-03-10 |
| 20220072140 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR MT1-MMP - The present invention relates to polypeptides which are covalently bound to aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of membrane type 1 metalloprotease (MT1-MMP), such as the collagen binding site of MT1-MMP. The invention also describes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups which have utility in imaging and targeted cancer therapy. | 2022-03-10 |
| 20220072141 | PROTEIN-DRUG CONJUGATES COMPRISING CAMPTOTHECIN ANALOGS AND METHODS OF USE THEREOF - Described herein are protein-drug conjugates and compositions thereof that are useful, for example, for target-specific delivery of therapeutic moieties, e.g., camptothecin analogs and/or derivatives. In certain embodiments, provided are specific and efficient methods for producing protein-drug constructs (e.g., antibody-drug conjugates) utilizing a combination of transglutaminase and 1,3-cycloaddition techniques. Camptothecin analogs, antibody-drug conjugates, and compositions which comprise glutaminyl-modified antibodies and camptothecin analog payloads and are provided. | 2022-03-10 |
| 20220072142 | ASH1L DEGRADERS AND METHODS OF TREATMENT THEREWIT - Provided herein are small molecules comprising a first domain that binds to ASH1L and a second domain that facilitates ASH1L degradation. In particular, ASH1L-targeting proteolysis targeting chimeras (PROTACs) and methods of use thereof for the treatment of disease (e.g., acute leukemia, solid cancers and other diseases dependent on activity of ASH1L) are provided. | 2022-03-10 |
| 20220072143 | Peptide Oligonucleotide Conjugates - Provided herein are oligonucleotides, peptides, and peptide-oligonucleotide-conjugates. Also provided herein are methods of treating a muscle disease, a viral infection, or a bacterial infection in a subject in need thereof, comprising administering to the subject oligonucleotides, peptides, and peptide-oligonucleotide-conjugates described herein. | 2022-03-10 |
| 20220072144 | TREATMENT OF HER3-MUTATED CANCER BY ADMINISTRATION OF ANTI-HER3 ANTIBODY-DRUG CONJUGATE - A therapeutic agent for HER3-mutated cancer containing an anti-HER3 antibody-drug conjugate as an active ingredient and/or a method of treatment for cancer, the method including administering an anti-HER3 antibody-drug conjugate to a subject determined to have HER3-mutated cancer. | 2022-03-10 |
| 20220072145 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING - Disclosed herein are molecules and pharmaceutical compositions that induce an insertion, deletion, duplication, or alteration in an incorrectly spliced mRNA transcript to induce exon skipping or exon inclusion. Also described herein include methods for treating a disease or disorder that comprises a molecule or a pharmaceutical composition that induces an insertion, deletion, duplication, or alteration in an incorrectly spliced mRNA transcript to induce exon skipping or exon inclusion. | 2022-03-10 |
| 20220072146 | PEGYLATED DRUG-LINKERS FOR IMPROVED LIGAND-DRUG CONJUGATE PHARMACOKINETICS - The present invention provides Ligand-Drug Conjugates comprising a PEG Unit in a parallel orientation to the Drug Unit. The invention provides inter alia. Ligand-Drug Conjugates (LDCs), methods of preparing and using them, and intermediates thereof. The Ligand-Drug Conjugates are stable in circulation, yet capable of inflicting cell death on targeted cells or inhibiting proliferation of targeted cells once its drug cargo is released in the vicinity or within targeted cells. In principle embodiments, an LDC of the present invention is represented by the structure of Formula I. | 2022-03-10 |
| 20220072147 | COMPOUND FOR PREPARATION OF ANTIBODY-PAYLOAD CONJUGATE AND USE THEREOF - The present application relates to a novel linker for use in bioconjugation, comprising two or more electrophilic carbon atoms of a carbonyl group, and a click chemistry functional group and, more specifically, to a linker through which a compound, a peptide, and/or a protein can be directly and/or indirectly linked by a substitution reaction to a desired target molecule, that is, a target molecule. | 2022-03-10 |
| 20220072148 | Novel Methionine Containing Antibodies for Conjugation of Agents - Provided herein are novel antibody-agent conjugates formed by the introduction of methionine residues to antibody scaffold light or heavy chains at select positions, followed by conjugation of the agent to the methionine, for example, by oxaziridine chemistries. Methionine substitutions at the targeted positions enable highly efficient functionalization to form very stable conjugates, including conjugates suitable for in vivo use. The positions were identified for the trastuzumab and other related scaffolds which can be engineered for affinity to any target antigen. The conjugates include ADCs and detections agents. Also disclosed are novel oxaziridine reagents for conjugation to methionines in proteins. | 2022-03-10 |
| 20220072149 | BIOLOGICALLY ACTIVE CLUSTER OF MOLECULES - The invention relates to a molecular scaffold suitable for covalently binding at least one biologically active molecule to a carrier molecule, the scaffold comprising a polymeric structure and the biologically active molecules covalently bound to said polymeric structure, and wherein the scaffold further comprises a chemical group for covalently coupling of the scaffold to the carrier molecule. The biologically active molecule has a molecular weight of 3.000 Dalton or less, such as 1.700 Dalton-1.950 Dalton. The biologically active molecule is an amphiphilic molecule in some embodiments. The biologically active molecule is a single specific molecule or is a mixture of different types of molecules, when more than one biologically active molecules are covalently bound to the polymeric (or oligomeric) structure. In particular, the invention relates to monoclonal antibody-based antibody-drug conjugates with improved therapeutic window of the drug due to covalent linkage of (a cluster of) potentiator molecules, e.g. a payload such as a protein toxin or oligonucleotide to the ADC, or alternatively, due to co-administration of an ADC and a cell-targeting conjugate comprising (a cluster of) potentiator molecules to a patient in need thereof. The invention also relates to a method for producing a scaffold suitable for covalently binding a biologically active molecule to a carrier molecule, providing a cluster of potentiator molecules. Furthermore, the invention relates to a method for producing a scaffold covalently bound to a carrier molecule, the scaffold comprising a covalently bound biologically active molecule, the carrier molecule comprising an antibody and a payload. | 2022-03-10 |
| 20220072150 | BRAIN-PENETRATING LIGAND AND DRUG CARRIER - An exemplary substance is provided that permeates the blood-brain barrier and shows a property of penetrating into the brain. Further, exemplary use of the substance as a drug carrier is provided for delivering into the brain, and a pharmaceutical composition containing the substance. Additionally, exemplary lactose-modified cyclodextrin or dendrimer/glucuronyl glucosyl-cyclodextrin is provided that permeates the blood-brain barrier and shows a property of penetrating into the brain. Exemplary blood-brain barrier permeable pharmaceutical composition is also provided which comprises a lactose-modified cyclodextrin or dendrimer/glucuronyl glucosyl-cyclodextrin, and a drug. | 2022-03-10 |
| 20220072151 | Methods and Gene Therapy Constructs for Treating GM2 Gangliosidoses - Disclosed are novel gene therapy constructs containing both HEXA and HEXB genes to treat GM2 gangliosidoses, including Sandhoff disease and Tay-Sach's disease. Also described are co-treatments using chaperone and anti-inflammatory agents to enhance the effects of gene therapy. | 2022-03-10 |
| 20220072152 | Composition and Methods for Treatment of Ornithine Transcarbamylase Deficiency - The present invention provides, among other things, methods of treating ornithine transcarbamylase deficiency, including administering to a subject in need of treatment a composition comprising an mRNA encoding an ornithine transcarbamylase protein at a low dose and at an administration interval such that at least one symptom or feature of the OTC deficiency is reduced. | 2022-03-10 |
| 20220072153 | REGENERATING FUNCTIONAL NEURONS FOR TREATMENT OF DISEASE AND INJURY IN THE NERVOUS SYSTEM - Methods for producing new neurons in the brain in vivo are provided according to aspects of the present invention which include introducing NeuroD1 into a glial cell, particularly into a reactive astrocyte or NG2 cell, thereby “converting” the reactive glial cell to a neuron. Methods of producing a neuronal phenotype in a glial cell are provided according to aspects of the present invention which include expressing exogenous NeuroD1 in the glial cell, wherein expressing exogenous NeuroD1 includes delivering an expression vector, such as a viral expression vector, including a nucleic acid encoding the exogenous NeuroD1 to the glial cell. | 2022-03-10 |
| 20220072154 | NEGATIVELY CHARGED PEG-LIPID CONJUGATES - The invention provides PEG-conjugated lipids of formula (I): A-B-C (I) wherein A, B, and C have any of the values defined in the specification, as well as compositions comprising the PEG-conjugated lipids of formula (I), nucleic acid lipid nanoparticles comprising the PEG-conjugated lipids of formula (I), and methods of using the PEG-conjugated lipids of formula (I), the compositions, and the nucleic acid nanoparticles. | 2022-03-10 |
| 20220072155 | NOVEL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS - Compounds are provided having the following structure: | 2022-03-10 |
| 20220072156 | PREVENTION OF MUSCULAR DYSTROPHY BY CRISPR/CAS9-MEDIATED GENE EDITING - Duchenne muscular dystrophy (DMD) is an inherited X-linked disease caused by mutations in the gene encoding dystrophin, a protein required for muscle fiber integrity. The disclosure reports CRISPR/Cas9-mediated gene editing (Myo-editing) is effective at correcting the dystrophin gene mutation in the mdx mice, a model for DMD. Further, the disclosure reports optimization of germline editing of mdx mice by engineering the permanent skipping of mutant exon (exon 23) and extending exon skipping to also correct the disease by post-natal delivery of adeno-associate virus (AAV). AAV-mediated Myo-editing can efficiently rescue the reading frame of dystrophin in mdx mice in vivo. The disclosure reports means of Myo-editing-mediated exon skipping has been successfully advanced from somatic tissues in mice to human DMD patients-derived iPSCs (induced pluripotent stem cells). Custom Myo-editing was performed on iPSCs from patients with differing mutations and successfully restored dystrophin protein expression for all mutations in iPSCs-derived cardiomyocytes. | 2022-03-10 |
| 20220072157 | COMPLEMENT FACTOR I AND COMPLEMENT FACTOR I COFACTOR, VECTORS ENCODING THEREFOR AND THERAPEUTIC USE - A product comprising (i) a Complement Factor I (CFI) cofactor; and (ii) Complement Factor I (CFI), or nucleotide sequences encoding therefor, as a combined preparation for simultaneous, separate or sequential use in therapy. | 2022-03-10 |
| 20220072158 | ISL1-BASED GENE THERAPY TO TREAT HEARING LOSS - Compositions for the prevention, treatment and/or reversal of hearing loss include vectors encoding an Islet-1 (Isl1) nucleic acid sequence. The over-expression of Isl1 molecules in ear cells, for example, hair cells, results in the treatment of hearing loss due to age, noise exposure or any idiopathic causes. | 2022-03-10 |
| 20220072159 | COMPOSITIONS AND METHODS FOR EXPRESSION OF MULTIPLE BIOLOGICALLY ACTIVE POLYPEPTIDES FROM A SINGLE VECTOR FOR TREATMENT OF CARDIAC CONDITIONS AND OTHER PATHOLOGIES - The present invention provides compositions and methods useful for treating disorders amenable to therapy via introduction of multigenic expression vectors. More particularly, the invention provides vectors and polynucleotides encoding polypeptides for treatment of cardiac disorders wherein said polypeptides may comprise a cytokine, a chemokine, and/or an angiogenic polypeptide, or functional derivatives thereof. Also provided, as compositions of the invention, are linkers useful for connecting and expressing functional (biologically active) polypeptides from single, multigenic-expression constructs. | 2022-03-10 |
| 20220072160 | COMPOSITIONS AND METHODS FOR PROMOTING HOMOLOGY DIRECTED REPAIR - This application provides improved methods of genome editing. Cas9 molecules can be used to create a break in a genomic region of interest. To increase the likelihood that the break is repaired by HDR (homology-directed repair), the cell can be contacted with molecules that bring a template nucleic acid in close proximity to the break, under conditions that allow the cell to repair the break using the template nucleic acid. | 2022-03-10 |
| 20220072161 | GRAPHENE QUANTUM DOTS-GADOLINIUM ION CHELATE AS MAGNETIC RESONANCE IMAGING CONTRAST AGENT AND PREPARATION METHOD THEREOF - A graphene quantum dots-gadolinium ion chelate (Gd@GQDs) nanomaterial with hydrophilic groups on the surface has a preparation method that includes: preparing graphene oxide by using a Hummers method; subsequently, subjecting the graphene oxide to heating, oxidation, and purification to obtain pure graphene quantum dots; and finally, chelating the graphene quantum dots with Gd | 2022-03-10 |
| 20220072162 | MAGNETIC RESONANCE IMAGING DRUG CONTAINING A DEUTERATED NATURAL BRANCHED-CHAIN AMINO ACID, AND DIAGNOSTIC METHOD USING SAID DRUG - The invention relates to the means for magnetic resonance imaging of oncological diseases and other diseases, accompanied by a locally altered level of absorption of nutrients by cells. The invention is the diagnostic drug containing at least one deuterated derivative of a natural branched-chain amino acid, as well as the diagnostic method based on the use of this diagnostic drug. The method of the invention includes performing magnetic resonance imaging and/or deuterium magnetic resonance spectroscopy after administration of the diagnostic drug in a time sufficient for the accumulation of the diagnostic drug in a target area of a subject's body. The proposed method allows to carry out a highly informative diagnostics of oncological diseases and other diseases, accompanied by a locally altered level of absorption of nutrients by cells. | 2022-03-10 |
| 20220072163 | MILD AND SITE-SELECTIVE 18F-LABELING OF SMALL MOLECULES AND/OR BIOMOLECULES VIA A THIOL-REACTIVE SYNTHON - Site-selective conjugation to biomolecules via thiol-based chemistry is superior to the unselective modification of lysine residues, which produce a mixed product and can potentially interfere with binding affinity of the biomolecule. However, in physiological environments, the maleimide-thiol conjugation product which is the current gold-standard for site-selective thiol-conjugation can be susceptible to hydrolysis or a retro-Michael reaction via exchange with reactive thiols such as those in albumin or glutathione residues yet the degradation is relatively slow. Therefore, for in vivo studies, the maleimide-thiol conjugation proposes instability issues. The compositions and methods disclosed herein provide an alternative thiol-based linkage, one that overcomes the instability issues with conventional reagents and methods. The compositions and methods disclosed herein are useful in various contexts, for example, for | 2022-03-10 |
| 20220072164 | RADIOACTIVE I-LABELED LAROTRECTINIB COMPOUND AND PREPARATION METHOD AND APPLICATION THEREOF - The invention relates to a radioactive I-labeled Larotrectinib compound and a preparation method and application thereof, including a radioactive I-labeled Larotrectinib compound having the following structural formula and its analogs: | 2022-03-10 |
| 20220072165 | RADIODRUG FOR DIAGNOSTIC/THERAPEUTIC USE IN NUCLEAR MEDICINE AND RADIO-GUIDED MEDICINE - Radio-drug suitable for performing radio-guided surgery, imaging diagnostics, radio-metabolic therapy. | 2022-03-10 |
| 20220072166 | METHOD OF TREATMENT OF NEUROENDOCRINE TUMORS - The present invention relates to methods of treating cancers that overexpress somatostatin receptors, e.g. neuroendocrine tumors (NET). In particular, the invention provides novel therapies based on the combination of a peptide receptor radionuclide therapeutic (PRRT) agent and immuno-oncology (I-O) therapeutic agents, wherein said I-O therapeutic agents are selected from the group consisting of LAG-3 inhibitors, TIM-3 inhibitors, GITR angonists, TGF-β inhibitors, IL15/IL-15RA complex, and selected PD-1 inhibitors. | 2022-03-10 |
| 20220072167 | Methods for Treating Cancer Using Combinations of PARP Inhibitors and Antibody Radioconjugates - This invention provides a method for treating a subject afflicted with cancer, comprising administering to the subject (i) a PARP inhibitor in conjunction with (ii) a radioisotope-labeled agent that targets cancer cells in the subject, wherein the amounts of the PARP inhibitor and labeled agent, when administered in conjunction with one another, are therapeutically effective. This invention also provides a method for inducing the death of a cancer cell, comprising contacting the cell with (i) a PARP inhibitor in conjunction with (ii) a radioisotope-labeled agent that targets the cancer cell, wherein the amounts of PARP inhibitor and labeled agent, when concurrently contacted with the cell, are effective to induce the cell's death. | 2022-03-10 |
| 20220072168 | LIGHT SOURCE DEVICE, AND STERILIZING/DEODORIZING DEVICE - Provided is a new light source device using an excimer lamp, particularly, a light source device for sterilization and deodorization. The light source device includes an excimer lamp and a flyback-type lighting device that supplies power to the excimer lamp. The lighting device includes a transformer, a switching element, and a control circuit that supplies a drive signal to the switching element. The control circuit controls the switching element on and off so that the switching frequency (FS) for the switching element at the time of starting to light is lower than the switching frequency (FO) at the time of steady-state lighting, and the ON-duty (TS) for the switching element at the time of starting to light is lower than the ON-duty (TO) at the time of steady-state lighting. | 2022-03-10 |
| 20220072169 | Ultraviolet Disinfection for a Water Bottle - Disinfection of a surface, such as a mouthpiece of a water bottle, using ultraviolet radiation is disclosed. A cover assembly can include a cover configured to selectively enclose the surface to be disinfected, such as the mouthpiece. The cover assembly can be configured such that ultraviolet radiation can be emitted into an interior volume at least partially formed by the cover and including the surface. The cover assembly can further include a power source which provides power to one or more ultraviolet light sources that emit the ultraviolet radiation. The cover assembly can be a mouthpiece cover assembly physically separate from a container and top cover or integrated in the top cover. A container and a top cover including one or more features for improved cleanliness are also disclosed. | 2022-03-10 |
| 20220072170 | IONIC OXIDATION REFRESHING SYSTEM AND METHOD - An ionic oxidation refreshing system for refreshing an odorized item, comprising an enclosure with an airflow system to contact the odorized item on all sides; an ionization system that produces a positively charged ionized ozone gas mixture inside of the enclosure, killing germs, including odor-causing bacteria, viruses, molds, and fungus, and provides the odorized item inside the enclosure with a net positive charge; a filter that neutralizes and filters out any toxic by-products; an electrostatic liquid atomization system that creates a fine mist of a quick-cleaning solution, and, in conjunction with the airflow system, causes solution droplets to penetrate deep into the odorized item and agitate a surface of the odorized item, ensuring the formula is evenly delivered onto the odorized item without over saturating any area. | 2022-03-10 |
| 20220072171 | SHOE SOLE DISINFECTION DEVICE - The invention discloses a shoe sole disinfection device, comprising at least one body, and a receiving structure. The body and the receiving structure are connected to each other by a first main pipe. As a result, the liquid storing in the receiving structure may flow through the first main pipe to the body when the shoes are disposed on the body, and it thus released to the sole for shoes, to enable disinfection for the shoe sole. | 2022-03-10 |
| 20220072172 | APPARATUS FOR GENERATING AQUEOUS OZONE - An apparatus includes a first production line configured to generate aqueous ozone with a first ozone concentration. The apparatus also includes an additional production line configured to generate aqueous ozone with an additional ozone concentration. The first production line and the additional production line include a flow switch, where fluid is configured to flow through the flow switch. The first production line and the additional production line include an ozone generator, where the ozone generator is configured to generate ozone when the fluid flows through the flow switch. The first production line and the additional production line include a fitting coupled to the flow switch and the ozone generator, where the fitting is configured to combine the generated ozone and the fluid to generate the aqueous ozone. The first production line is configured to generate aqueous ozone independently from the additional production line. | 2022-03-10 |
| 20220072173 | Fogger Disinfectant Device - This present invention relates to a portable fogger disinfectant device which is used to disperse a novel disinfecting and sanitizing solution and related propellant to disinfect a room or other enclosed space. The spray material is stored in a pressure-activated cylinder with a nozzle, a sensor and a timer. In one embodiment, the disinfecting and sanitizing solution is comprised of an ethanol, an alkyl comprised of C14, C12, and C16, water as a base for other ingredients, fragrance oils, ethanolamine, a propellant and an ammonium hydroxide. | 2022-03-10 |
| 20220072174 | System and Method for Sterilizing Cash Exchanges - A system and method sterilizes cash exchanges. The system includes a sanitization system and a transaction station. The transaction station may any type of transaction station such as, but not limited to, a teller window, a vacuum air tube (VAT) station, or an automated teller machine (ATM). The transaction station includes a user access area. The user access area is the main access point for the user when executing a transaction. For example, the user access area can be a transaction drawer, a tubular container and a container-receiving pocket, or a user ATM interface. The sanitization system includes an ultraviolet light (UVL) device which is the primary means to sterilize a cash exchanged being executed by the user. The sanitization system also includes a covering mechanism which is used to enclose the user access area in order to prevent a user from being exposed to ultraviolet (UV) lighting. | 2022-03-10 |
| 20220072175 | User Equipment Having Multiple Subscriber Identity Modules with Improved Suspend / Resume Operation - Devices and associated methods for operating a dual-subscriber identity module (SIM) dual-standby (DSDS) user equipment device (UE) configured with a first SIM and a second SIM. The UE performs communications with a first cellular network using the first SIM and a first radio resource control (RRC) connection, and receives a request to perform a higher priority communication using the second SIM. In response to the request to perform the higher priority communication, the UE transmits a request to the first network to suspend the first RRC connection. After transmission of the request to suspend the first RRC connection, the UE receives a message from the first network to place the first RRC connection in an inactive state, and initiates a timer, wherein the timer is used to determine whether the first RRC connection remains in the inactive state or transitions to an idle state. | 2022-03-10 |
| 20220072176 | Purified Hydrogen Peroxide Gas Microbial Control Methods and Devices - The present invention relates to methods and devices for providing microbial control and/or disinfection/remediation of an environment. The methods generally comprise: generating a Purified Hydrogen Peroxide Gas (PHPG) that is substantially free of, e.g., hydration, ozone, plasma species, and/or organic species; and directing the gas comprising primarily PHPG into the environment such that the PHPG acts to provide microbial control and/or disinfection/remediation in the environment, preferably both on surfaces and in the air. | 2022-03-10 |
| 20220072177 | HYGIENE SYSTEM AND METHOD FOR OPERATING A HYGIENE SYSTEM - The present invention relates to a hygiene system comprising
| 2022-03-10 |
| 20220072178 | SCENT CONTROL DEVICE AND METHODS FOR TREATING AN ENVIRONMENT - Systems and methods to treat an environment. The system includes a plurality of scent control material sources configured to output a scent control material (e.g., an oxidant) into the environment to reduce pathogens, dispose of scent molecules and their sources, and otherwise treat the environment. The system can include a controller communicatively coupled to the plurality of scent control material sources and cause one or more subsets of the plurality of scent control material sources to individually or collectively output scent control material into the environment. | 2022-03-10 |
| 20220072179 | DEVICE FOR DIFFUSING VOLATILE SUBSTANCES - The device for diffusing volatile substances comprises a body ( | 2022-03-10 |
